NasdaqGM - Nasdaq Real Time Price USD

Biodesix, Inc. (BDSX)

1.3800 +0.0500 (+3.76%)
As of 9:49 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Scott Hutton President, CEO & Director 614.92k -- 1972
Ms. Robin Harper Cowie CFO, Secretary & Treasurer 390.3k -- 1980
Mr. Kieran O'Kane Chief Commercial Officer 392.61k -- 1977
Dr. Heinrich Röder Founder & CTO -- -- --
Mr. Christopher Vazquez VP, Controller & Chief Accounting Officer -- -- --
Mr. Mark DeBlock Vice President of Sales -- -- --
Mr. Robbie Lunt Senior Director of Marketing -- -- --
Ms. Jessica Olbricht Senior Director of Human Resources -- -- --
Dr. Gary Anthony Pestano Ph.D. Chief Development Officer -- -- 1967
Ms. Bobbi Coffin Chief Growth Officer -- -- --

Biodesix, Inc.

919 West Dillon Road
Louisville, CO 80027
United States
303 417 0500 https://www.biodesix.com
Sector: 
Healthcare
Full Time Employees: 
217

Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Corporate Governance

Biodesix, Inc.’s ISS Governance QualityScore as of June 1, 2024 is 10. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 5, 2024 at 10:59 AM UTC - August 9, 2024 at 12:00 PM UTC

Biodesix, Inc. Earnings Date

Recent Events

June 6, 2024 at 12:30 PM UTC

at Jefferies Heathcare Conference

June 4, 2024 at 3:40 PM UTC

at William Blair Growth Stock Conference

May 24, 2024 at 12:00 AM UTC

S-1/A: Offering Registrations

May 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 8, 2024 at 8:30 PM UTC

Q1 2024 Earnings Call

May 8, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 26, 2024 at 12:00 AM UTC

ARS: Annual Report to Shareholders

April 23, 2024 at 12:00 AM UTC

S-1: Offering Registrations

April 16, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

April 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers